Biosynex SA (EPA:ALBIO)

Market Cap	20.62M -20.0%
Revenue (ttm)	115.13M -5.9%
Net Income	-58.22M
EPS	n/a
Shares Out	18.75M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	828,663
Average Volume	68,686
Open	1.300
Previous Close	1.100
Day's Range	1.250 - 1.570
52-Week Range	0.455 - 1.590
Beta	0.77
RSI	86.56
Earnings Date	May 14, 2026

About Biosynex

Biosynex SA designs, manufactures, and distributes rapid diagnostic tests to patients and healthcare professionals in France and internationally. The company develops and markets IVDs in the form of RDTs and TRODs, immunoblot, molecular biology, and POC for screening, diagnosis, and prevention. It also provides thermometers, tensiometers, oximetry, hearing protection products, oral and dental hygiene products, self-tests, thermal pads, inhalation chambers, and thermotherapy products. The company was founded in 1993 and is based in Illkirch-Graf...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1993
• Employees: 454
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALBIO

Financial Performance

In 2024, Biosynex's revenue was 101.17 million, an increase of 8.81% compared to the previous year's 92.98 million. Losses were -43.33 million, 17.3% more than in 2023.